EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Bioanalytical Strategy for the Characterization and Bioanalysis of Biologics: A Global, Nonregulated Bioanalytical Lab Perspective

Hetal Sarvaiya iD, Shuai Niu, Daniel T Ladror iD, Yuting Wang iD, Dolonchampa Maji iD, Malerie Wolke, Paramasivam Natarajan, Gary J Jenkins

Bioanalysis · 2023

DOI: 10.4155/bio-2022-0215 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Bioanalysis, 2023. Verfasst von Hetal Sarvaiya und 7 weiteren Autor:innen. Beteiligte Einrichtung: DMPK-BA, AbbVie Inc., South San Francisco, CA 94080, USA. Hauptthemen laut MEDLINE: Biological Products. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the past two decades, we have seen an increase in the complexity and diversity of biotherapeutic modalities pursued by biopharmaceutical companies. These biologics are multifaceted and susceptible to post-translational modifications and in vivo biotransformation that could impose challenges for bioanalysis. It is vital to characterize the functionality, stability and biotransformation products of these molecules to enable screening, identify potential liabilities at an early stage and devise a bioanalytical strategy. This article highlights our perspective on characterization and bioanalysis of biologics using hybrid LC-MS in our global nonregulated bioanalytical laboratories. AbbVie's suite of versatile, stage-appropriate characterization assays and quantitative bioanalytical approaches are discussed, along with guidance on their utility in answering project-specific questions to aid in decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biological ProductsLaboratoriesChromatography, LiquidMass SpectrometryBiotransformation

Stichwörter der Autor:innen

antibody–drug conjugatesbioanalysisbiologicsbiotransformationcellular dispositioncharacterizationhybrid LC–MSligand-binding assaypharmacokineticpost-translational modificationsstability

Substanzen

Biological Products

Autor:innen und Institutionen

  • DMPK-BA, AbbVie Inc., South San Francisco, CA 94080, USA.
  • DMPK-BA, AbbVie Inc., Worcester, MA 01605, USA.
  • DMPK-BA, AbbVie, Inc., North Chicago, IL 60064, USA.

ORCID-Profile: Hetal Sarvaiya, Daniel T Ladror, Yuting Wang, Dolonchampa Maji

Förderung

  • AbbVie

Zitieren

APA

Sarvaiya, H., Niu, S., Ladror, D. T., Wang, Y., Maji, D., Wolke, M., Natarajan, P., & Jenkins, G. J. (2023). Bioanalytical Strategy for the Characterization and Bioanalysis of Biologics: A Global, Nonregulated Bioanalytical Lab Perspective. Bioanalysis. https://doi.org/10.4155/bio-2022-0215

Vancouver

Sarvaiya H, Niu S, Ladror DT, Wang Y, Maji D, Wolke M, et al. Bioanalytical Strategy for the Characterization and Bioanalysis of Biologics: A Global, Nonregulated Bioanalytical Lab Perspective. Bioanalysis. 2023. doi:10.4155/bio-2022-0215

BibTeX
@article{Sarvaiya2023,
  author = {Sarvaiya, Hetal and Niu, Shuai and Ladror, Daniel T and Wang, Yuting and Maji, Dolonchampa and Wolke, Malerie and Natarajan, Paramasivam and Jenkins, Gary J},
  title = {Bioanalytical Strategy for the Characterization and Bioanalysis of Biologics: A Global, Nonregulated Bioanalytical Lab Perspective},
  journal = {Bioanalysis},
  year = {2023},
  doi = {10.4155/bio-2022-0215}
}
Kostenlos starten →